Vaxcyte, Inc.
PCVX
Rangering i aksjer
#2085
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage,... Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
Aksjekurs
$64.29
Sist synkronisert: 2026-10-19
Markedsverdi
$9.86B
Endring (1 dag)
1.05%
Endring (1 år)
49.86%
Land
US
Handel Vaxcyte, Inc. (PCVX)
Kategori
Healthcare
Antall utestående aksjer for Vaxcyte, Inc. (PCVX)
Antall utestående aksjer per June 2026: 144.49M
Ifølge Vaxcyte, Inc. sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 144.49M. Ved slutten av December 2023 hadde selskapet 97.16M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Vaxcyte, Inc. (PCVX) fra 2017 til 2026
Utestående aksjer ved utgangen av hvert år
| År | Utestående aksjer | Endre |
|---|---|---|
| 2026 (TTM) | 144.49M | 18.44% |
| 2024 | 122.00M | 25.57% |
| 2023 | 97.16M | 49.75% |
| 2022 | 64.88M | 24.95% |
| 2021 | 51.92M | 75.74% |
| 2020 | 29.55M | 678.52% |
| 2019 | 3.80M | 4.57% |
| 2018 | 3.63M | 1.80% |
| 2017 | 3.57M | 0.00% |
Utestående aksjer for lignende selskaper eller konkurrenter
| Selskap | Utestående aksjer | Forskjell | Land |
|---|---|---|---|
| 253.90M | 75.72% |
US
|
|
| 396.00M | 174.06% |
US
|
|
| 478.91M | 231.44% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -56.96% |
NL
|
